Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSLCQ-908 is an inhibitor of diacylglycerol acyltransferase 1 (DGAT1; IC50 = 57 nM).1 It is selective for DGAT1 over DGAT2, acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1), and ACAT-2 (IC50s = >10,000 nM for all). LCQ-908 (50 µM) also inhibits hepatitis C virus (HCV) replication in HCV-infected Huh7.5 cells.2 It inhibits palmitic acid-induced apoptosis and increases in triglyceride levels in MIN6 pancreatic β-cells when used at a concentration of 1 µM.3 In vivo, LCQ-908 (1 mg/kg) decreases serum triglyceride levels in an oral lipid tolerance test in dogs.1
WARNING This product is not for human or veterinary use.
1. Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-
2. A diacylglycerol transferase 1 inhibitor is a potent hepatitis C antiviral in vitro but not in patients in a randomized clinical trial. ACS Infect. Dis. 3(2), 144-151 (2017).
3. DGAT1 inhibitors protect pancreatic β-